Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

New targeted therapy shows promise in patients with ALK-positive advanced NSCLC

An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.

4 Dec 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of Hematology (ASH) annual meeting December 6-9, and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 9-13.

2 Dec 2014

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

Overcoming graft rejection is the main obstacle when it comes to stem cell regeneration or organ transplantation.

2 Dec 2014

U of T professor wins GSK's 2014 Discovery Fast Track Challenge devoted for cancer research

University of Toronto (U of T) Professor Tania Watts is a winner of GSK's 2014 Discovery Fast Track Challenge, which is designed to accelerate the translation of academic research into novel therapies.

2 Dec 2014

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics, Inc.today announced the acceptance of a Type II variation application for IMBRUVICA (ibrutinib) by the European Medicines Agency.

1 Dec 2014

CTI BioPharma announces upcoming presentations of pacritinib data at ASH Annual Meeting

CTI BioPharma Corp. (CTI) today announced the upcoming presentations of data highlighting pacritinib, an oral multikinase inhibitor with dual activity against JAK2 and FLT3, and tosedostat, an oral selective inhibitor of aminopeptidases, at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9 in San Francisco, CA.

1 Dec 2014

Plymouth professor awarded grant to find effective treatment for patients with mantle cell lymphoma

Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer Research UK to carry out a research study into the treatment of older patients with mantle cell lymphoma.

27 Nov 2014

Researchers uncover easily detectable, 'pre-malignant' state in the blood

Researchers from the Broad Institute of MIT and Harvard, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, "pre-malignant" state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome.

27 Nov 2014

Researchers discover new method to deliver drugs into aggressive tumors

A multi-disciplinary team of Yale Cancer Center researchers has discovered a promising new method for delivering drugs into aggressive tumors by exploiting a unique feature of tumors themselves.

21 Nov 2014

Alliance for Balanced Pain Management established to support appropriate access to pain management

A diverse collective of health care advocacy groups, patient organizations, industry representatives and other stakeholders today announced they have established the Alliance for Balanced Pain Management (AfBPM) to support appropriate access to integrated pain management and responsible use of prescription pain medicines with an aim to reduce abuse.

21 Nov 2014

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

Juno Therapeutics, Inc. announced today that the FDA has granted Orphan Drug Designation to its JCAR015 chimeric antigen receptor product candidate. The designation was granted for treatment of acute lymphoblastic leukemia. JCAR015 Phase I trials are currently underway at Juno's collaboration partner, Memorial Sloane Kettering Cancer Center.

18 Nov 2014

Walter and Eliza Hall Institute receives $2.5 million grant to support cancer research

Australian cancer researchers will gain access to first-in-Australia technology through new funding from Australian Cancer Research Foundation to the Walter and Eliza Hall Institute. The $2.5 million grant will allow the establishment of the ACRF Breakthrough Technologies Laboratory, providing new insights into how cancer develops, and how it can be more effectively treated. The laboratory is one of four initiatives announced by ACRF last night.

13 Nov 2014

Researchers refine diagnostic tools to predict treatment outcomes for children with neuroblastoma

Oncology researchers studying gene mutations in the childhood cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations. Removing some of the guesswork in diagnosis and treatment, the researchers say, may lead to more successful outcomes for children with this often-deadly cancer.

11 Nov 2014

Researchers develop 'smart bomb' to attack B-lineage ALL

Fatih Uckun, Jianjun Cheng and their colleagues have taken the first steps towards developing a so-called "smart bomb" to attack the most common and deadly form of childhood cancer — called B-lineage acute lymphoblastic leukemia (ALL).

6 Nov 2014

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.

4 Nov 2014

Findings could lead to single blood test for early detection of many types of cancer

Scientists have identified more than 800 markers in the blood of cancer patients that could help lead to a single blood test for early detection of many types of cancer in future, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Sunday).

3 Nov 2014

Newly-identified cancer cell fingerprints in the blood could help diagnose childhood cancer

Newly-identified cancer cell fingerprints in the blood could one day help doctors diagnose a range of children's cancers faster and more accurately, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference next week.

3 Nov 2014

Melbourne researchers reveal key steps involved in programmed cell death

Melbourne researchers have uncovered key steps involved in programmed cell death, offering new targets for the treatment of diseases including lupus, cancers and neurodegenerative diseases.

31 Oct 2014

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information's report, Stem Cell Therapeutics Markets.

31 Oct 2014

Study: Obese youths with ALL have worse outcomes than lean counterparts

Obese youths with acute lymphoblastic leukemia (ALL) are known to have worse outcomes than their lean counterparts. To find out why, investigators at Children's Hospital Los Angeles studied patients who were obese at the time of their diagnosis with ALL to determine if body mass index (BMI) impacted response to initial chemotherapy. This response to initial chemotherapy (or induction therapy) is measured by the absence of leukemia cells in the bone marrow.

28 Oct 2014

Lymphoma News and Research

Further Reading

New targeted therapy shows promise in patients with ALK-positive advanced NSCLC

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

U of T professor wins GSK's 2014 Discovery Fast Track Challenge devoted for cancer research

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

CTI BioPharma announces upcoming presentations of pacritinib data at ASH Annual Meeting

Plymouth professor awarded grant to find effective treatment for patients with mantle cell lymphoma

Researchers uncover easily detectable, 'pre-malignant' state in the blood

Researchers discover new method to deliver drugs into aggressive tumors

Alliance for Balanced Pain Management established to support appropriate access to pain management

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

Walter and Eliza Hall Institute receives $2.5 million grant to support cancer research

Researchers refine diagnostic tools to predict treatment outcomes for children with neuroblastoma

Researchers develop 'smart bomb' to attack B-lineage ALL

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

Findings could lead to single blood test for early detection of many types of cancer

Newly-identified cancer cell fingerprints in the blood could help diagnose childhood cancer

Melbourne researchers reveal key steps involved in programmed cell death

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Study: Obese youths with ALL have worse outcomes than lean counterparts

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News